EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Precision medicine for gastric cancer patients guided by molecular classifications

Min-Kyue Shin, Jae-Ho Cheong

Foregut Surgery · 2023

DOI: 10.51666/fs.2023.3.e8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Foregut Surgery, 2023. Verfasst von Min-Kyue Shin und 1 weiteren Autor:innen. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic treatment outcomes remain poor in stage IV gastric cancer (GC) patients, with a 5-year survival rate of less than 5%-10%.The development of molecular-targeted and immunotherapeutic agents is setting new standards in recent years.A human epidermal growth factor receptor 2 (HER2) inhibitor, trastuzumab, and 2 programmed cell death protein 1 (PD-1) inhibitors, pembrolizumab and nivolumab, have been approved as a firstline treatment of GC by the U.S. Food and Drug Administration.Furthermore, a claudin 18.2 targeting agent, zolbetuximab, and a fibroblast growth factor receptor 2 (FGFR2) isoform IIb-targeting agent, bemarituzumab, are likely to be approved as a first-line treatment of GC in the next few years.Moreover, the vascular endothelial growth factor receptor-2 (VEGFR2) antagonist, ramucirumab, and an antibody-drug conjugate containing an anti-HER2 antibody, trastuzumab deruxtecan, have demonstrated significant benefits in patients previously treated for GC.Companion diagnostics are essential for appropriate candidate selection for targeted treatment.Next-generation sequencing enables the robust and highthroughput screening of biomarkers, significantly improving clinical outcomes in prospective umbrella trials.Recent advances in tumor molecular profiling have provided unprecedented opportunities for developing precision cancer medicine based on deeper understanding of tumor biology.In The Cancer Genome Atlas STAD study, tumors with Epstein-Barr virus infection or microsatellite instability showed a favorable prognosis.In contrast, genomically stable tumors with mesenchymal gene expression showed a dismal clinical outcome.More recently, a clinical-grade molecular assay that is a single patient-level classifier, nProfiler ® 1, was developed to classify GC into molecular subtypes, which are prognostic and predictive of chemotherapy response.Owing to the lack of effective therapeutics for advanced or recurrent metastatic GC, novel therapeutic approaches are being developed specifically for the therapyrefractory subtype and the establishment of preclinical models.Considering the spatial and temporal heterogeneity within a patient's tumor, future precision oncology studies require further development of combinatorial and/or sequential treatment strategies based on the molecular subtype of the cancer.

Zitieren

APA

Shin, M., & Cheong, J. (2023). Precision medicine for gastric cancer patients guided by molecular classifications. Foregut Surgery. https://doi.org/10.51666/fs.2023.3.e8

Vancouver

Shin M, Cheong J. Precision medicine for gastric cancer patients guided by molecular classifications. Foregut Surgery. 2023. doi:10.51666/fs.2023.3.e8

BibTeX
@article{Shin2023,
  author = {Shin, Min-Kyue and Cheong, Jae-Ho},
  title = {Precision medicine for gastric cancer patients guided by molecular classifications},
  journal = {Foregut Surgery},
  year = {2023},
  doi = {10.51666/fs.2023.3.e8}
}
Kostenlos starten →